International access

Is OpenEvidence Available Outside the US?

OpenEvidence is a US-centered clinical AI product. This page summarizes what international clinicians should know before assuming access or compliance outside the United States.

Updated May 24, 2026 · 7 minute read

Direct Answer

OpenEvidence should not be treated as broadly available outside the United States. Its privacy policy says most OpenEvidence companies and much of its technical infrastructure are in the US, that personal data is transferred to the US, and that users in the EU or countries with stricter privacy laws than the US should not use OpenEvidence because it is not governed or protected by EU safeguards. Separately, 2026 reporting says OpenEvidence withdrew from the EU and UK. For clinicians outside the US, availability, verification, data protection, and local clinical AI regulation should be checked country by country.

Source: Clinical AI Report, 2026

Key takeaways

OpenEvidence is clearly US-centered in its privacy and infrastructure language.

EU and UK access is publicly reported as unavailable as of spring 2026.

Outside the US, the safest assumption is not that OpenEvidence is globally available, but that availability must be verified locally.

International alternatives should be compared on access, evidence quality, data transfers, local privacy law, and medical software obligations.

Current availability signals

Primary market

United States

OpenEvidence's public positioning, privacy policy, and technical infrastructure language are US-centered, and some product announcements specify access for verified US healthcare professionals.

Reported unavailable

United Kingdom

Public reporting says OpenEvidence access was terminated in the UK in spring 2026, with regulatory uncertainty cited in coverage.

Reported unavailable

European Union

OpenEvidence is publicly reported as withdrawn from the EU, and its privacy policy warns EU users not to use the service because it is not protected by EU safeguards.

Verify locally

Other non-US countries

For countries outside the US, EU, and UK, do not infer availability from US marketing. Check clinician verification, privacy-law fit, data transfers, and local medical software rules.

What OpenEvidence says about users outside the United States

The most important primary source is OpenEvidence's own privacy policy. It says OpenEvidence Inc. and most group companies are located in the United States, that much of the platform infrastructure and hosting are in the US, and that personal data may be transferred to the US.

  • •The policy tells users in the EU or countries with stricter privacy laws than the US not to use OpenEvidence or related services.
  • •It states that EU safeguards do not govern or protect the service for those users.
  • •It also notes that personal information may be available to US government agencies under US legal process.

Where OpenEvidence is publicly reported as unavailable

The clearest public availability reports concern the EU and UK. Telecare Aware reported access termination in the UK and EU on April 30, 2026, and CH Health Tech Advisory described OpenEvidence as withdrawn from the EU and UK.

  • •For the EU, the issue is tied to privacy safeguards and regulatory uncertainty around AI systems.
  • •For the UK, reporting says access was also terminated even though the UK is outside the EU.
  • •For other countries, public evidence is less complete, so the page should not claim a universal global block.

What international clinicians should ask before using any workaround

A VPN or informal workaround does not solve the underlying compliance question. If the product is not offered for your country, local clinicians and organizations still need to consider data transfers, professional duties, procurement rules, and whether the product is appropriate for clinical use in that jurisdiction.

  • •Can your country's clinicians register and verify credentials through the normal process?
  • •Does the vendor contract in your jurisdiction and provide data processing terms?
  • •Where is data hosted and which subprocessors can access it?
  • •Does your local regulator treat the feature as clinical decision support, medical-device software, or a lower-risk reference tool?

How to choose an alternative outside the US

The best alternative depends on the country and the workflow. An international buyer should separate availability from product quality: a tool can be clinically strong but unsuitable if it cannot meet local data, safety, or procurement expectations.

  • •For AI-native CDS, check Vera Health's global availability and GDPR positioning, then verify local contracting and data terms.
  • •For institutional reference content, check UpToDate availability through individual or hospital licensing.
  • •For evidence summaries and AI reference workflows, check DynaMed or Dyna AI availability in your region.
  • •For any tool, require clear source citations, clinical limitations, human oversight, and a local governance owner.

Related Clinical AI Report pages

Is OpenEvidence available in the UK?

A UK-specific access and regulatory context page for OpenEvidence.

Vera Health review

Review Vera Health as an AI-native CDS alternative with international availability signals.

OpenEvidence alternatives

Compare OpenEvidence alternatives by workflow, evidence, and clinical use case.